The New Immune-Oncology Checkpoint Therapy Trial Paradigm

COVID-19 disruption is, for now, curbing innovation in the immune-oncology (IO) checkpoint space and driving a reorientation of clinical trial priorities. Are we now at a turning point for the next generation of these promising cancer therapies?

This thought paper sets out the current scenario as well as the future potential for the Immune Checkpoint Inhibitor landscape. It is based on Beacon’s unbiased comprehensive analysis of current clinical trials sourced from scientifically curated and up-to-date information from all publicly available sources. Beacon Checkpoint is a sector-specific database that includes trial and drug records for preclinical, active, approved, and discontinued Immune Checkpoint Modulator Combinations and Monotherapies across 28 checkpoint targets.

Home > Checkpoint Thought Paper 2020

Beacon Checkpoint - The New Immune-Oncology Checkpoint Therapy Trial Paradign - Dec 2020

We highlight some of the key topics discussed in the thought paper below. However to read the full paper – click below

Download Now

Covid-19 implications for trial registrations

With the unprecedented number of new investigational agents and companies in IO, it is difficult to track the current agents in clinical development and their clinical trials progress. Yet more challenging is making an assessment of the likely impact of the coronavirus pandemic. (Download the article to find out more)

COVID-19 Caution in the Clinic

While the trend for combination trials shows no sign of slowing at present, the impact of the pandemic for R&D cannot be ignored.

Pre-COVID-19, combination therapies under consideration for future investigation in a clinical setting – such as the interaction of PD(L1) and chemotherapy – were being widely explored.

Post-COVID-19, and the attainment of synergy with such assets now appears more complex due to the risk of immune-mediated adverse effects. This main factor here is that the interplay of COVID-19 and the immune system has been associated with the development of Acute Respiratory Distress Syndrome (ARDS).

The ‘next normal’ for the checkpoint trial space

The specific trial issues caused by the COVID-19 pandemic are likely to continue providing researchers with obstacles to navigate for the short to medium term – or at least until widespread adoption and availability of authorized COVID-19 vaccines heralds a resumption of normal activities. (Download the article to find out more)

Find out more

This insight and data is part of the subscription to Beacon Checkpoint.

Beacon Checkpoint Logo

Find out more

Speak with our Team

Our dedicated Sales and Research teams can help you with questions by showing you how this insight and data is collated on Beacon

Request a Demo

About Beacon Targeted Therapies

We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more